Adding bevacizumab to chemotherapy for soft tissue sarcoma
Part of Cancer clinical trials.
This trial compares a standard two-drug chemotherapy (gemcitabine and docetaxel) with the same drugs plus an added medication called bevacizumab (Onbevzi) that targets blood vessel growth to starve tumors. It is for people with certain types of advanced soft tissue sarcoma who have already had some prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these sarcoma types: leiomyosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma, or angiosarcoma.
- You must have had 1 to 2 prior chemotherapy treatments (chemotherapy before or after surgery counts as one).
- You must be between 19 and 80 years old.
- You must be able to care for yourself and be up and about (performance status 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- Your liver, kidney, and blood counts should be within acceptable ranges (the study team will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Hear when a new Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.